SAN DIEGO, Feb. 8, 2011 /PRNewswire/ -- Marshall Edwards, Inc.(Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present an update on Marshall Edwards and its lead oncology programs at the BIO CEO & Investor Conference on Monday, February 14, 2011 at 11:00 a.m. EST from the Waldorf-Astoria in New York. A live webcast of the presentation can be accessed at www.veracast.com/webcasts/bio/ceoinvestor2011/01106133.cfm.
About Marshall Edwards
Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company’s lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The first and most advanced is a NADH oxidase inhibitor program that includes Phenoxodiol and its next-generation drug candidate NV-143. The second is a mitochondrial inhibitor program that includes NV-128 and its next-generation candidate NV-344. Both programs are expected to advance into the clinic in 2011. For more information, please visit www.marshalledwardsinc.com.
SOURCE Marshall Edwards, Inc.
